Neoadjuvant Chemo May Improve Outcomes for MIBC of Variant Histology
Findings refute the notion that variant histology MIBC will not respond to neoadjuvant chemotherapy.
Findings refute the notion that variant histology MIBC will not respond to neoadjuvant chemotherapy.
The full approval was based on data from the confirmatory phase 3 KEYNOTE-361 trial.
Real-world data validate recently reported findings from clinical trials.
The nomograms predicted overall and progression-free survival.